Reference antibody targeting TNFRSF7/CD27, based on the Organon patent. Used in immunotherapy research to modulate T-cell activation and co-stimulation. Targets the CD27 receptor, a member of the tumor necrosis factor receptor superfamily, to influence immune responses. Investigated for potential in cancer immunotherapies, particularly in enhancing anti-tumor activity through immune system engagement. Also applied in studies of autoimmune diseases and immune checkpoint pathways. Its design supports functional blocking or receptor activation, depending on experimental context, making it a tool for probing CD27-CD70 signaling in disease models. Serves as a standard reference for commercial antibody production.